2. Antibody-drug Conjugate/ADC Related Immunology/Inflammation Cell Cycle/DNA Damage
  3. Antibody-Drug Conjugates (ADCs) Transmembrane Glycoprotein Topoisomerase
  4. Precemtabart tocentecan

Precemtabart tocentecan  (Synonyms: Precem-TcT; M 9140)

Cat. No.: HY-177434
Handling Instructions Technical Support

Precemtabart tocentecan (Precem-TcT; M 9140) is an anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) antibody-drug conjugate (ADC). Precemtabart tocentecan consists of a tumor-specific anti-CEACAM5 monoclonal antibody Precemtabart (HY-P990940), a highly hydrophilic and stable cleavable β-glucuronide linker, and a topoisomerase 1 inhibitor payload Exatecan (HY-13631), and the drug-linker conjugate for ADC is Mal-Gly-PAB-Exatecan-D-glucuronic acid (HY-153179). Precemtabart tocentecan inhibits the growth of CEACAM5-positive cancer cells. Precemtabart tocentecan exhibits significant antitumor activity in CEACAM5-expressing xenograft models. Precemtabart tocentecan can be used for the study of CEACAM5-expressing advanced solid tumors, especially mCRC.

For research use only. We do not sell to patients.

Precemtabart tocentecan

Precemtabart tocentecan Chemical Structure

CAS No. : 2873366-83-5

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Precemtabart tocentecan Related Antibodies

Top Publications Citing Use of Products

View All Topoisomerase Isoform Specific Products:

View All Isoforms
Topoisomerase Topo I Topo II

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Precemtabart tocentecan (Precem-TcT; M 9140) is an anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) antibody-drug conjugate (ADC). Precemtabart tocentecan consists of a tumor-specific anti-CEACAM5 monoclonal antibody Precemtabart (HY-P990940), a highly hydrophilic and stable cleavable β-glucuronide linker, and a topoisomerase 1 inhibitor payload Exatecan (HY-13631), and the drug-linker conjugate for ADC is Mal-Gly-PAB-Exatecan-D-glucuronic acid (HY-153179). Precemtabart tocentecan inhibits the growth of CEACAM5-positive cancer cells. Precemtabart tocentecan exhibits significant antitumor activity in CEACAM5-expressing xenograft models. Precemtabart tocentecan can be used for the study of CEACAM5-expressing advanced solid tumors, especially mCRC[1].

IC50 & Target[1]

Topoisomerase I

 

In Vitro

Precemtabart tocentecan (0.09-0.63 nM, 144 h) potently inhibits the viability of CEACAM5-positive SK-CO-1 and MKN45 cells, with IC50 values of 0.09 nM and 0.63 nM respectively[1].
Precemtabart tocentecan (1 nM, 6 days) induces cell death in CEACAM5-negative MDA-MB-231 cells when co-cultured with CEACAM5-positive SK-CO-1 cells, and the effect is enhanced with increasing number of SK-CO-1 cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Precemtabart tocentecan Related Antibodies
In Vivo

Precemtabart tocentecan (6 mg/kg, i.v., once on day 0) exerts potent antitumor activity, achieving tumor stasis in CEACAM5-high COPF230 or REPF210 cancer-derived xenograft model[1].
Precemtabart tocentecan (4 mg/kg, i.v., once every 2 weeks for 3 doses) exerts potent antitumor activity in Irinotecan (HY-16562A)-pretreated CXF4102 CRC PDX model[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: COPF230 or REPF210 tumor fragments were subcutaneously implanted into the right flanks of 5-6-week-old female immunodeficient mice[1]
Dosage: 6 mg/kg
Administration: i.v., once on day 0
Result: Achieved tumor stasis (-29% tumor volume on day 52) in COPF230 model and tumor regression (-72% tumor volume on day 52) in REPF210 model.
Animal Model: CXF4102 tumor fragments were subcutaneously implanted into the right flanks of 6-8-week-old female immunodeficient mice[1]
Dosage: 4 mg/kg
Administration: i.v., once every 2 weeks for 3 doses
Result: Induced substantial tumor regression (-73% tumor volume on day 32) with sustained inhibition (-57% tumor volume on day 60) in irinotecan-pretreated CXF4102 model.
CAS No.
SMILES

[Precemtabart tocentecan]
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Precemtabart tocentecan Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Precemtabart tocentecan2873366-83-5Precem-TcT M 9140M9140M 9140M-9140Antibody-Drug Conjugates (ADCs)Transmembrane GlycoproteinTopoisomeraseAntibody-Drug Conjugatesantibody-drug conjugateCEACAM5topoisomerase 1cancersInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Precemtabart tocentecan
Cat. No.:
HY-177434
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.